Newsletter Signup | Join Community
CLL is treated with chemotherapy, precision medicines and most recently with CAR T, now with remissions of > 8 years.
Management of Acute Myeloid Leukemia: Induction, Consolidation, Precision Medicines and Stem Cell Transplantation.
Research suggests some patients with CML can safely discontinue TKI therapy - NCCN guidelines published.
Drug resistance can occur when CML no longer responds to a TKI and there are a number of possible causes
Tibsovo approved for treatment of newly diagnosed and relapsed Acute Myeloid Leukemia with an IGH1 mutation
Bosulif superior to early generation TKI's for treatment of Chronic Myelogenous Leukemia
Gazyva improves survival and delays the CLL progression.
Blincyto prolongs survival in relapsed/refractory adult ALL and can be used in combination with other medications.
Stay Current With Leukemia Treatment Advances & Connect with Others
FDA Approves Precision Medicine Enasidenib as new Targeted Treatment for individuals with AML and IDH2 genetic mutation
Trisonex (arsenic) has become an effective and standard treatment for all phases of acute promyelocytic leukemia.
Diagnosis, useful terms and treatment of chronic myeloid leukemia - chronic phase.
Overview of CML Accelerated & Blastic Phases
Copiktra approved by FDA for treatment of CLL and SLL
Chemotherapy in Addition to Interferon May not Improve Survival for Newly Diagnosed CML
Dr Zent M.D. and colleagues report on relationship between leukemia and risk of developing melanoma.
Venclexta® Promising in Newly Diagnosed Acute Myeloid Leukemia
Cancer Connect - Relapsed Childhood Acute Lymphoblastic Leukemia
Cancer Connect - Relapsed Chronic Lymphocytic Leukemia
Cancer Connect - Relapsed or Refractory Adult Acute Lymphoblastic Leukemia
Treatment overview of recurrent or relapsed Acute Myeloid Leukemia
Cancer Connect - Treatment of Childhood Acute Lymphoblastic Leukemia
Cancer Connect - Treatment of Adult Acute Lymphoblastic Leukemia
Arzerra™ precision cancer medicine effective for treatment of newly diagnosed and refractory CLL
Gene editing expands reach of therapeutic T cells, in mice
Campath® can be safely combined with Rituxan, Fludara and other medications to treat CLL.
Novel Agent may Reverse Resistance to Targeted Therapy in Acute Leukemia and MDS
FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia
CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia
The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor
Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia
Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic
CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin
CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin
Allogenic stem cell transplant is a curative treatment option for individuals with newly diagnosed and recurrent AML.
FDA Approves Rydapt for Treatment of Acute Myeloid Leukemia
Venclexta® and Low-doses of Cytarabine Effective in Elderly with Acute Myeloid Leukemia
FDA Grants Iclusig® Expanded Approval for CML
Discovery of Ezh2 May Represent New Treatment Option for Chronic Myelogenous Leukemia
LLS Launches Groundbreaking Precision Medicine Approach To Treat AML
Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin Improves Progression-Free Survival in Acute Leukemia
Pracinostat Receives Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed
FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment
GlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia
CancerConnect Launches Online Community for Patients Diagnosed with Histiocytosis
Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia.
Vyxeos™ Improves Survival for Elderly in AML.
Midostaurin Receives Breakthough Therapy Designation for Acute Myeloid Leukemia.
Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review.
Reduced Treatment for AML and MDS Patients Undergoing Stem Cell Transplant.
Addition of Rituxan Improves Outcomes in Some Acute Lymphoblastic Leukemias.
Midostaurin Improves Survival in Subset of Acute Myeloid Leukemia
Cyclosporin A Reduces Anthracycline Resistance in Acute Myeloid Leukemia
Zelboraf® Appears Active in Hairy Cell Leukemia That Has Progressed After Other Treatment
CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Tasigna® Remains Superior to Gleevec® for Treatment of Newly Diagnosed Patients With Chronic Myeloid Leukemia
Intravenous Administration of Erwinaze® Approved by FDA
Actinium Receives Orphan-drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed
CD19-Directed CAR T Cells Effective in Management of Relapsed/Refractory Acute Lymphoblastic Leukemia
Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment.
SYNRIBO® Approved for use in Chronic Myeloid Leukemia
Link Between Allergies and Blood Cancers in Women
Mylotarg Reduces Risk of Relapse in Childhood AML
Busulfex Superior to Total Body Irradiation in AML in First Remission
CPX-351 Highly Active in Older Patients with AML
Combination of Revlimid and Vidaza Beneficial in Untreated Elderly Patients with AML
Iclusig Approved for CML and ALL
Tasigna Superior to Gleevec for Philadelphia Chromosome-Positive CML
Synribo Approved for CML
Marqibo Approved for Treatment of Philadelphia-Negative ALL
Ponatinib Produces High Response Rates in CML.
FDA Priority Review Granted for Midostaurin in Leukemia
Low Doses of Mylotarg May Improve Survival in Older Patients with Acute Myeloid Leukemia.
One Subset of Childhood Acute Lymphoblastic Leukemia is Best Treated with Chemotherapy.
Adult Acute Lymphoblastic LeukemiaOverview
Acute Myeloid Leukemia Screening/PreventionOverview
Mini-Transplants Continue to Show Promise for Older Patients with AML.
New Warning Added to Sprycel Label.
Tasigna Continues to Show Benefit for Newly Diagnosed CML.
Bosutinib Evaluated for Initial Treatment of Patients with CML.
Inotuzumab Ozogamicine Effective for Patients in Refractory-Relapse (R-R) of ALL.
Dacogen Effective for Treating Elderly Patients with Acute Myeloid Leukemia (AML)
New Chemotherapy Regimen Benefits Children and Young Adults with ALL.
CML Patients Treated with Gleevec Have Normal Life Expectancy.
Childhood Cancer Survivors Facing Cognitive Challenges May Benefit from Methylphenidate
Newly Diagnosed Ph+ ALL Patients May Benefit from Sprycel/Chemotherapy Combination
Mylotarg Withdrawn from Market in United States
Sprycel May Be More Effective than Gleevec for Initial Treatment of CML
Study Evaluates Anthracycline-related Heart Problems in Childhood Cancer Survivors
Survivors of Some Childhood Cancers May Face Cognitive Impairment
Drinking During Pregnancy May Increase Leukemia Risk in Child
Mylotarg Effective for Older Intermediate-risk AML Patients
Fludara plus Rituxan Extends Survival in CLL
High-dose Chemotherapy with Cerubidine® Significantly Prolongs Survival in Acute Myeloid Leukemia
HemeScan™ Evaluates Prognosis in Chronic Lymphocytic Leukemia
Rituxan Approved for Chronic Lymphocytic Leukemia.
Tasigna May Be More Effective than Gleevec for Initial Treatment of CML.
Treanda® and Rituxan® Effective Initial Therapy for CLL.
Advances in the Management of Chronic Myeloid Leukemia:
Mini Transplants Provide Benefit in Patients with CLL Who Have Stopped Responding to Fludara®
Allogeneic Stem Cell Transplantation Improves Survival for Intermediate and Poor-risk AML.
Genasense® Improves Long-term Survival in Recurrent Chronic Lymphocytic Leukemia
Sprycel® Superior to High-dose Gleevec® in Gleevec-resistant CML.
Eliminating Preventive Radiation in Children with ALL.
Compressed Dose-dense Induction with S-HAM Effective and Less Toxic for AML Patients.
MicroRNA Expression Associated with Disease Progression in (CLL).
Abnormal Cells Identified in Blood Years Before Diagnosis of CLL.
Sprycel® Gets Full Approval for Adults with Chronic Myeloid Leukemia
Prolonged Maintenance Therapy for Poor-Prognosis Acute Myeloid Leukemia may Reduce Relapses
Vaccine for Chronic Myelogenous Leukemia Shows Promise
Early Allogeneic Stem Cell Transplants Benefit Intermediate-Risk Acute Myeloid Leukemia
Survival and Response to Treatment Among Elderly Patients with Acute Myeloid Leukemia.
Recent Steroid Treatment Increases Risk of Severe Chickenpox
Early Allogeneic Stem Cell Transplant May Not be Optimal for Certain Patients with Low-Risk CML
Allogeneic Stem Cell Transplants Effective for Long-Term Remission of CLL
Activated Macrophages and Rituxan™ Promising for CLL
Peripheral Blood Monitoring Instead of Bone Marrow Effective in Children Treated with Acute Lymphoblastic Leukemia
Anti-BCL2 Agent Sensitizes Refractory Leukemia to Chemotherapy
Parental Use of Some Medications Associated with Increased Incidence of Childhood Acute Lymphocytic Leukemia
FDA Approves STI157 Efficacy for Chronic Myelogenous Leukemia
Genetic Alterations Can Determine Optimal Treatment Options for Patients with Acute Myeloid Leukemia
Higher Dose Post-Remission Chemotherapy Consolidation Treatment of Acute Myelogenous Leukemia Improves Cure and Survival
Allogeneic Mini-Transplants Effective and Safer for Advanced CLL
Allogeneic Transplant Using Peripheral Blood Stem Cells Is Associated with Faster Blood Count Recovery
Allogeneic Bone Marrow Transplantation Indicated for Children with Philadelphia- Positive ALL
Allogeneic and Autologous Stem Cell Transplantation Effective Post Remission Treatments for Adult ALL
Acute megakaryocytic leukemia is a rare type of leukemia that occurs mainly in adults.
Novel Agent Shows Anti-Leukemic Activity
Consolidation Therapy May Improve Autologous Stem Cell Transplant Efficacy in AML Patients with Favorable Cytogenetics
Acute Myeloid Leukemia: New Test Helps Predict Relapse, Counter with More Intensive Therapy
Recurrent AML: Antibody-Targeted Therapy, Gemtuzumab Ozogamicin, under FDA Priority Review for Older Persons
Further Data Supporting Bone Marrow Transplantation in First Complete Remission for High-Risk ALL Patients
Growth Hormone Appears to Stimulate Height Increase in Pediatric Patients Treated for Acute Lymphoblastic Leukemia
Gemtuzumab Ozogamicin A Safe and Effective Treatment Option for Patients with Relapsed Acute Myeloid Leukemia
E Coli-Asparaginase Superior to Erwinia-Asparaginase for Pediatric ALL
Addition of Thalidomide Not Effective in Acute Myelogenous Leukemia or Myelodysplastic Syndromes
According to a recent article published in
Chronic Myelogenous Leukemia: New Molecular Test May Identify Time to Progression to Acute Disease